Comparative controlled clinical trial of pivmecillinam and nalidixic acid in patients with acute simple urinary tract infections.
We performed a controlled double-blind clinical study with PMPC to investigate its therapeutic usefulness in acute simple cystitis in comparison with NA, with the results as follows: 1. In both treatment groups, PMPC proved to be remarkably more active (MIC) than NA against the bacterial isolates tested in vitro. 2. PMPC, administered in dosis (200 mg per day) one-tenth those of NA (2,000 mg per day), produced a greater improvement (therapeutic effects) than NA. 3. Side-effects were apparently less frequent with PMPC, as compared to NA. The results indicate a remarkable usefulness of PMPC in the treatment of acute simple cystitis.
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000561:Amdinocillin Pivoxil / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001419:Bacteria / Q000187:drug effects; D002986:Clinical Trials as Topic; D003556:Cystitis / Q000188:drug therapy* / Q000382:microbiology; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009268:Nalidixic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010397:Penicillanic Acid / Q000627:therapeutic use*; D010403:Penicillin Resistance
D000561:Amdinocillin Pivoxil; D009268:Nalidixic Acid; D010397:Penicillanic Acid